Biogen names McKenzie EVP pharmaceutical operations, technology

CAMBRIDGE, Mass. — Biogen on Thursday announced named Paul McKenzie as its EVP pharmaceutical operations and technology, effective July 1.  McKenzie, who was previously the company’s SVP global biologics manufacturing and technical operations, will head the company’s asset management, technical development, supply chain operations, global manufacturing, quality and engineering. 

 

“With his extensive technical and development expertise, we believe Paul is ideally suited to lead the next phase of growth across Biogen’s development and manufacturing operations,” Biogen CEO George Scangos said. “He will play an essential role, building upon our tradition of world-class manufacturing while leading the development of next-generation capabilities to ensure global availability of our current and future therapies.”

 

McKenzie, who will also oversee the construction and operations of the company’s biologics manufacturing facility in Solothurn, Switzerland, joined Biogen from Johnson & Johnson in February. He had most recently been J&J’s VP research and development for its Ethicon business, having previously led manufacturing and technical operations for internal and external manufacturing of Janssen’s pharmaceutical portfolio. 

 

“This is an exciting time to be at Biogen, and I am honored to take the reins of pharmaceutical operations and technology from John Cox, who has been instrumental in creating one of the best teams in the industry and driving leading-edge innovation and operations for our clinical and commercial portfolio,” McKenzie said. “Our team will continue to build on a very successful track record of safety, quality and reliability to advance our diverse portfolio in biologics, oligonucleotides, gene therapy and small molecules.”